Business Context and Reporting Period
This Form 8-K was filed by Oncocyte Corporation (trading symbol: OCX) on April 5, 2024, with the report date of April 11, 2024. The filing discloses the entry into a material definitive agreement with Bio-Rad Laboratories, Inc. The company is incorporated in California and its common stock is listed on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing is a current report regarding a corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes and Agreements
The primary material change is the execution of a 10-year Collaboration Agreement with Bio-Rad Laboratories, Inc. Key terms include:
- Scope: Collaboration on developing and commercializing GraftAssure (research use only) and VitaGraft (in vitro diagnostic) transplant monitoring assays using Bio-Rad's ddPCR instruments.
- Roles: Oncocyte will manufacture assays and conduct validation; Bio-Rad will supply instruments, reagents, and consumables.
- Commercial Rights: Oncocyte holds exclusive rights to sell research use only assays in the U.S. and Germany, paying Bio-Rad a single-digit royalty on net sales. Bio-Rad holds exclusive rights outside this territory.
- Option: Bio-Rad has an option to obtain exclusive worldwide rights to promote, market, and sell the in vitro diagnostic kits. Exercising this option requires Bio-Rad to purchase additional shares of Oncocyte common stock at the then-current market price up to a specified maximum aggregate purchase price.
Outlook, Risks, and Management Commentary
Management views this agreement as a strategic step to leverage Bio-Rad's ddPCR platform for the commercialization of Oncocyte's transplant monitoring products. The agreement includes a joint steering committee to oversee development. The filing notes that the summary is qualified by the full Collaboration Agreement, which will be filed in the upcoming Form 10-Q. No specific financial guidance or risk factors beyond standard termination provisions were detailed in this specific text.
Investor Verification Checklist
- Verify the specific "specified maximum aggregate purchase price" for the stock purchase option, as the exact figure is not disclosed in this summary.
- Review the full Collaboration Agreement (to be filed in the Q1 2024 Form 10-Q) for detailed termination clauses and intellectual property rights.
- Confirm the timeline for the commercial launch of the GraftAssure and VitaGraft assays.
- Assess the impact of the single-digit royalty rate on future gross margins for sales within the U.S. and Germany.